Idexx Laboratories
IDXX stock analysis · Health Care · Health Care Equipment
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-06-30. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-06-30 · -61.3% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
14 industry peers · median 25.4×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 39.2× · -35.5% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy · parent-equity fallback (scope limitation) · short-term borrowing coverage incomplete
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Annual basis · read assumptions below
How this is calculated ↗Accrual quality
Parent-earnings fallback versus consolidated cash flow · scope limitation
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $255.33 | $278.59 | $303.60 |
| 10.0% | $187.11 | $203.57 | $221.25 |
| 12.0% | $147.61 | $160.17 | $173.64 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 4.3B | 1.1B | 1.2B | 124.7M | 3.4B |
| 2024-12-31 | 3.9B | 887.9M | 929M | 120.9M | 3.3B |
| 2023-12-31 | 3.7B | 845M | 906.5M | 133.6M | 3.3B |
| 2022-12-31 | 3.4B | 679.1M | 543M | 148.8M | 2.7B |
| 2021-12-31 | 3.2B | 744.8M | 755.5M | 119.5M | 2.4B |
| 2020-12-31 | 2.7B | 582.1M | 648.1M | 107M | 2.3B |
| 2019-12-31 | 2.4B | 427.8M | 459.2M | 155M | 1.8B |
| 2018-12-31 | 2.2B | 377M | 400.1M | 115.8M | 1.5B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 4.3B | RevenueFromContractWithCustomerExcludingAssessedTax | 2026-02-20 |
| netIncome | 1.1B | NetIncomeLoss Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2026-02-20 |
| Parent/common earnings proxy | 1.1B | NetIncomeLoss | 2026-02-20 |
| cfo | 1.2B | NetCashProvidedByUsedInOperatingActivities | 2026-02-20 |
| capex | 124.7M | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-20 |
| operatingIncome | 1.4B | OperatingIncomeLoss | 2026-02-20 |
| assets | 3.4B | Assets | 2026-02-20 |
| equity | 1.6B | StockholdersEquity Parent-attributable fallback: a verified consolidated total is unavailable in the supported tags. Noncontrolling interests have not been assumed to be zero; this may differ in scope from consolidated cash flow or operating income. | 2026-02-20 |
| Parent book equity proxy | 1.6B | StockholdersEquity | 2026-02-20 |
| debt | 450M | LongTermDebt | 2026-02-20 |
| shortDebt | — | Not reported under a supported tag | — |
| cash | 180.1M | CashAndCashEquivalentsAtCarryingValue | 2026-02-20 |
| shares | 81M | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-20 |
| dividends | 0 | Reviewed manual correction This issuer explicitly confirms in its annual filing that it has never declared or paid cash dividends on its common/capital stock. Reviewed cash-dividend zero, bounded to fiscal period ending 2025-12-31. The exact statement and source filing are retained in the evidence record. This is explicit filing evidence, not an assumption from an absent cash-flow line. Surrounding source passage reviewed as the registrant’s own common-stock policy, not a subsidiary or predecessor statement. | 2026-02-20 |
| buybacks | 1.2B | PaymentsForRepurchaseOfCommonStock | 2026-02-20 |
| issuance | 93.4M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from exercises of stock options and employee stock purchase plans: 93362000 USD [us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions]. All 9 financing lines reconcile exactly to reported financing cash flow -1164964000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: issuance follows the separately reported common cash-inflow lines; it is not an independent verification of every gross equity transaction. | 2026-02-20 |